| P50 | author | Stephan Harbarth | Q63391550 |
| | Patrice François | Q87138615 |
| | İlker Uçkay | Q87399310 |
| | Jacques Schrenzel | Q87416031 |
| | Pierre Vaudaux | Q87416349 |
| | Adriana Renzoni | Q95998276 |
| | Elzbieta Huggler | Q114313632 |
| P2093 | author name string | Daniel P Lew | |
| | Louis Bernard | |
| | Tristan Ferry | |
| | Marta Buzzi | |
| P2860 | cites work | Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study | Q21195056 |
| | Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications | Q24646677 |
| | Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus | Q28478770 |
| | Vancomycin: we can't get there from here. | Q51608468 |
| | Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. | Q51785920 |
| | Effect of screening for methicillin-resistant Staphylococcus aureus carriage by polymerase chain reaction on the duration of unnecessary preemptive contact isolation. | Q54512743 |
| | Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients | Q77223457 |
| | Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus | Q80363319 |
| | Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence | Q80363323 |
| | Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets | Q83770914 |
| | Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia | Q83984006 |
| | A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 |
| | Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus | Q29619365 |
| | Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus. | Q30330106 |
| | Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patients | Q33500363 |
| | Exploring innate glycopeptide resistance mechanisms in Staphylococcus aureus | Q33762805 |
| | Use of an automated multiple-locus, variable-number tandem repeat-based method for rapid and high-throughput genotyping of Staphylococcus aureus isolates | Q33885060 |
| | Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. | Q34108614 |
| | Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study | Q34268116 |
| | Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections | Q34737617 |
| | Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 |
| | Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods | Q35541702 |
| | Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center | Q35784453 |
| | Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia | Q35879117 |
| | Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance | Q36692468 |
| | The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus | Q36779557 |
| | Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 |
| | Methicillin-resistant Staphylococcus aureus, Geneva, Switzerland, 1993-2005. | Q37008996 |
| | Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. | Q37274726 |
| | Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates | Q37809666 |
| | Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? | Q37837241 |
| | Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides | Q39465279 |
| | Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates | Q41877894 |
| | Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates | Q42153532 |
| | Vancomycin bactericidal activity as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia | Q42706371 |
| | Preferential emergence of reduced vancomycin susceptibility in health care-associated methicillin-resistant Staphylococcus aureus isolates during continuous-infusion vancomycin therapy in an in vitro dynamic model | Q42772417 |
| | Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods | Q42773139 |
| | Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus | Q42948108 |
| | Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years | Q43117809 |
| | Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used | Q43202070 |
| | Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection. | Q43233889 |
| | A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital | Q43552304 |
| | Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus | Q44755051 |
| | Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains | Q44828789 |
| | Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy | Q44959085 |
| | The problem with glycopeptides | Q45169360 |
| | Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin | Q45199316 |
| | High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 |
| | Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia | Q46130414 |
| | Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections | Q46431265 |
| | Heteroresistance: a concern of increasing clinical significance? | Q46841479 |
| | Effect of delayed infection control measures on a hospital outbreak of methicillin-resistant Staphylococcus aureus. | Q50665811 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | methicillin-resistant Staphylococcus aureus | Q595158 |
| | Staphylococcus aureus | Q188121 |
| P304 | page(s) | 1258-1264 | |
| P577 | publication date | 2011-12-12 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus | |
| P478 | volume | 56 | |